Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
US Army
Fish and Richardson
Daiichi Sankyo
Teva
McKesson
Covington
Boehringer Ingelheim
Johnson and Johnson
Cipla

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021178

« Back to Dashboard

NDA 021178 describes GLUCOVANCE, which is a drug marketed by Bristol Myers Squibb and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the GLUCOVANCE profile page.

The generic ingredient in GLUCOVANCE is glyburide; metformin hydrochloride. There are twenty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the glyburide; metformin hydrochloride profile page.
Summary for 021178
Tradename:GLUCOVANCE
Applicant:Bristol Myers Squibb
Ingredient:glyburide; metformin hydrochloride
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 021178
Suppliers and Packaging for NDA: 021178
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178 NDA Bristol-Myers Squibb Company 0087-6073 0087-6073-11 100 TABLET, FILM COATED in 1 BOTTLE (0087-6073-11)
GLUCOVANCE glyburide; metformin hydrochloride TABLET;ORAL 021178 NDA Bristol-Myers Squibb Company 0087-6074 0087-6074-11 100 TABLET, FILM COATED in 1 BOTTLE (0087-6074-11)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Jul 31, 2000TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Jan 14, 2020Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength2.5MG;500MG
Approval Date:Jul 31, 2000TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Jan 14, 2020Product Flag?Substance Flag?Delist Request?Y

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength5MG;500MG
Approval Date:Jul 31, 2000TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Jan 14, 2020Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Chinese Patent Office
Cerilliant
Daiichi Sankyo
McKesson
Johnson and Johnson
Mallinckrodt
Covington
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot